PAR paradigm biopharmaceuticals limited..

Ann: Notice of General Meeting/Proxy Form, page-50

  1. 1,506 Posts.
    lightbulb Created with Sketch. 185
    Hey KP, just wondering why can’t they sign the deal, and make the additional equity issue as a condition precedent? And they tell the market that we have a deal subject to shareholders’ approval of the additional share issue? In that scenario, the market will gladly approve the issue without a fuss. I see plenty of times agreement are signed, subject to X Y Z being ticked off before it comes into effect. Surely PAR could have been more transparent but they chose maximum opacity. To what ends, one can only speculate and it leaves room for people to, rightly or wrongly, conclude another CR is on the agenda.
    Last edited by Aviza2913: 30/04/25
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
29.5¢
Change
-0.015(4.84%)
Mkt cap ! $114.8M
Open High Low Value Volume
31.0¢ 31.0¢ 29.0¢ $67.50K 220.4K

Buyers (Bids)

No. Vol. Price($)
3 35330 29.0¢
 

Sellers (Offers)

Price($) Vol. No.
30.0¢ 44652 7
View Market Depth
Last trade - 13.04pm 18/06/2025 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.